Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Angiotensin receptor blockers (ARBs) is an effective and well tolerated first-line
antihypertensive drug. Fimasartan is a newly developed ARB that has not been compared
with other ARBs with regard to its efficacy and tolerability.